<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096003</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-1762</org_study_id>
    <nct_id>NCT02096003</nct_id>
  </id_info>
  <brief_title>Intrathecal Hydromorphone for Pain Control After Cesarean Section</brief_title>
  <official_title>Comparison of Intrathecal Hydromorphone and Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of intrathecal opioids for analgesia in the setting of cesarean section has become
      standard obstetric anesthesia practice. Currently, two opioids are commonly used. These
      opioids are fentanyl and morphine (Duramorph). Intrathecal opioids are an excellent source of
      analgesia and act to reduce the stress response to surgery.

      Currently, most obstetric anesthesiologists use intrathecal morphine for analgesia after
      cesarean delivery. Morphine provides excellent analgesia for cesarean section. However, use
      of this medication is associated with side effects such as pruritus and nausea and vomiting.

      Recently, multiple obstetric anesthesia groups began to use intrathecal hydromorphone for
      cesarean delivery when morphine was unavailable. As groups began to use hydromorphone,
      retrospective data became available that demonstrated its safety and efficacy for use during
      cesarean section.

      In order to fully elucidate the analgesic and side effect properties of hydromorphone for
      cesarean delivery, a prospective randomized, double blind study comparing morphine and
      hydromorphone is necessary. The investigators need to understand whether hydromorphone is as
      effective as morphine for analgesia after cesarean section, and whether it is associated with
      fewer or more side effects. The results of the study will allow providers to make educated
      decisions to better care for their patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 5, 2017</completion_date>
  <primary_completion_date type="Actual">May 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Operative Fentanyl PCA Consumption</measure>
    <time_frame>at 24 hours</time_frame>
    <description>Total dose of fentanyl patient controlled analgesia (pca) used in 24 hours post-op.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Initial PCA Use</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>When does the patient need to use the PCA for the first time? This will be used to assess when morphine and hydromorphone first begin to provide analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>at 24 hours</time_frame>
    <description>Assess pain scores on a scale of 1-5, with higher score indicating more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Score</measure>
    <time_frame>at 24 hours</time_frame>
    <description>Patient satisfaction score - total scale of 1-5, with higher score indicating more satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Scale for Two Specific Side Effects of Nausea and Pruritus</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Symptom scale for nausea and pruritus. Full scale from 1-5, with higher score indicating more symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal morphine</intervention_name>
    <description>0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.</description>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <other_name>Duramorph</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal hydromorphone</intervention_name>
    <description>50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.</description>
    <arm_group_label>Intrathecal hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective primary cesarean section

          -  Females age 18-40

        Exclusion Criteria:

          -  Emergency cesarean section

          -  Anesthetic other than spinal

          -  History of chronic pain or pre-op opioid use

          -  Allergy to morphine or hydromorphone

          -  BMI&gt;40
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaakov Beilin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <results_first_submitted>July 11, 2019</results_first_submitted>
  <results_first_submitted_qc>July 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Yaakov Beilin</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Intrathecal hydromorphone</keyword>
  <keyword>Intrathecal morphine</keyword>
  <keyword>Primary cesarean section</keyword>
  <keyword>Analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02096003/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in April 2014 with enrollment from May 2014 to May 2017</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intrathecal Morphine</title>
          <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
Intrathecal morphine: 0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.</description>
        </group>
        <group group_id="P2">
          <title>Intrathecal Hydromorphone</title>
          <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
Intrathecal hydromorphone: 50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>additional surgery</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intrathecal Morphine</title>
          <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
        </group>
        <group group_id="B2">
          <title>Intrathecal Hydromorphone</title>
          <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="5.1"/>
                    <measurement group_id="B2" value="33.75" spread="4.1"/>
                    <measurement group_id="B3" value="34.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Operative Fentanyl PCA Consumption</title>
        <description>Total dose of fentanyl patient controlled analgesia (pca) used in 24 hours post-op.</description>
        <time_frame>at 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Morphine</title>
            <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Hydromorphone</title>
            <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Fentanyl PCA Consumption</title>
          <description>Total dose of fentanyl patient controlled analgesia (pca) used in 24 hours post-op.</description>
          <units>µg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" spread="432"/>
                    <measurement group_id="O2" value="446" spread="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initial PCA Use</title>
        <description>When does the patient need to use the PCA for the first time? This will be used to assess when morphine and hydromorphone first begin to provide analgesia.</description>
        <time_frame>up to 24 hours</time_frame>
        <population>data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Morphine</title>
            <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Hydromorphone</title>
            <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initial PCA Use</title>
          <description>When does the patient need to use the PCA for the first time? This will be used to assess when morphine and hydromorphone first begin to provide analgesia.</description>
          <population>data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score</title>
        <description>Assess pain scores on a scale of 1-5, with higher score indicating more pain.</description>
        <time_frame>at 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Morphine</title>
            <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Hydromorphone</title>
            <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score</title>
          <description>Assess pain scores on a scale of 1-5, with higher score indicating more pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Score</title>
        <description>Patient satisfaction score - total scale of 1-5, with higher score indicating more satisfaction</description>
        <time_frame>at 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Morphine</title>
            <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Hydromorphone</title>
            <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Score</title>
          <description>Patient satisfaction score - total scale of 1-5, with higher score indicating more satisfaction</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="4.6" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Scale for Two Specific Side Effects of Nausea and Pruritus</title>
        <description>Symptom scale for nausea and pruritus. Full scale from 1-5, with higher score indicating more symptoms.</description>
        <time_frame>up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Morphine</title>
            <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Hydromorphone</title>
            <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Scale for Two Specific Side Effects of Nausea and Pruritus</title>
          <description>Symptom scale for nausea and pruritus. Full scale from 1-5, with higher score indicating more symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intrathecal Morphine</title>
          <description>0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections</description>
        </group>
        <group group_id="E2">
          <title>Intrathecal Hydromorphone</title>
          <description>50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Puritus</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yaakov Beilin</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-7467</phone>
      <email>yaakov.beilin@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

